09:49 AM EST - Theralase Technologies Inc. : Has demonstrated increased efficacy with its latest, patented, licensed, anti-cancer drug, TLD-1633, when compared to its lead anti-cancer drug, TLD-1433. Theralase Technologies Inc.
shares V.TLT are trading up $0.015 at $0.49.
